PTC Therapeutics (NASDAQ:PTCT) and ADMA Biologics (NASDAQ:ADMA) Critical Comparison

ADMA Biologics (NASDAQ:ADMA) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings for ADMA Biologics and PTC Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	3	3	0	2.50
PTC Therapeutics	2	2	10	1	2.67

ADMA Biologics presently has a consensus target price of $18.67, indicating a potential upside of 99.00%. PTC Therapeutics has a consensus target price of $99.08, indicating a potential upside of 58.10%. Given ADMA Biologics’ higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than PTC Therapeutics.

Earnings & Valuation

This table compares ADMA Biologics and PTC Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17 million	4.12	$146.93 million	$0.70	13.40
PTC Therapeutics	$1.01 billion	5.19	$682.64 million	($0.58)	-108.05

PTC Therapeutics has higher revenue and earnings than ADMA Biologics. PTC Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.7% of ADMA Biologics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ADMA Biologics and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Risk and Volatility

ADMA Biologics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Summary

ADMA Biologics beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.